Peter H. O’Donnell
Jacobi Medical Center(US)University of Chicago(US)University of Chicago Medical Center(US)PharmacoGenetics (China)(CN)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, Pharmacogenetics and Drug Metabolism, Cancer Genomics and Diagnostics
Most-Cited Works
- → Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial(2016)3,687 cited
- → First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study(2017)1,329 cited
- → Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma(2017)842 cited
- → Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer(2016)840 cited
- → Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy(2019)609 cited
- →